Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Source: Eur Respir J 2010; 36: 800-807 Year: 2010
VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009
Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004
Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006
Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Hypoxia-induced pulmonary hypertension: Synergistic effects of sildenafil and erythropoietin in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012
Roflumilast N- oxide combined with sildenafil reverses cellular remodeling on IPF models Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodeling in experimental pulmonary hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
Esterification of iloprost enhances its protective effects on pulmonary endothelium Source: Respiratory Failure and Mechanical Ventilation Conference 2020 Year: 2020
Dual endothelin-1 receptor antagonism prevents chronic intermittent hypoxia-induced cardiovascular alterations in rats Source: Annual Congress 2008 - Innovative treatments in sleep disordered breathing Year: 2008
Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways Source: Eur Respir J 2013; 41: 1116-1125 Year: 2013
Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012